Serrapeptase

Serrapeptase (Serratiopeptidase)

1. Identity and Names

Serrapeptase — also known as serratiopeptidase, serralysin, Serratia E-15 protease, serratiapeptase, serratia peptidase, serratio peptidase, and serrapeptidase — is a proteolytic enzyme of microbial origin with a well-characterized biochemical identity. Serratiopeptidase (Serratia E-15 protease, also known as serralysin, serrapeptase, serratiapeptase, serratia peptidase, serratio peptidase, or serrapeptidase) is a proteolytic enzyme (protease) produced by enterobacterium Serratia sp. E-15, now known as Serratia marcescens ATCC 21074.

Serratiopeptidase is a zinc-containing metalloprotease with a molecular weight of 45–60 kDa. The enzyme has an EC number 3.4.24.40 and belongs to the group Serralysin. The serrapeptase enzyme has a molecular weight of 45,000–60,000 Da and is comprised of 470 amino acids in length; it is classified as a metalloprotease due to containing a zinc molecule which helps catalyze its enzymatic activity. Although it shows maximal activity at 40°C and a pH of 9.0, it is fully inactivated at 55°C for 15 minutes and possesses an isoelectric point of 5.3. Its substrate specificity appears to be somewhat similar to that of thermolysin (produced from Bacillus thermoproteolyticus), and the amino acid sequence is free of sulfur-containing amino acids (cysteine and methionine).

The enzyme consists of 470 amino acids which are important for its proteolytic activity. The enzyme is devoid of sulfur-containing amino acids such as cysteine and methionine. The active site contains conserved histidine/glutamate residues that coordinate a Zn²⁺ ion (metalloprotease mechanism).

Natural Source

This microorganism was originally isolated in the late 1960s from silkworm (Bombyx mori L.) intestine. Serratiopeptidase is present in the silkworm intestine and allows the emerging moth to dissolve its cocoon. Serratiopeptidase is produced by purification from culture of Serratia E-15 bacteria.

Commercial Production and Regulatory Status

Today, serrapeptase is manufactured through microbial fermentation and is used as a dietary supplement due to its potential health benefits, particularly for helping support a healthy inflammatory response, respiratory health, and the body's natural recovery processes. Serrapeptase was first isolated from the gut bacteria of silkworms and later produced through controlled fermentation using the microorganism Serratia marcescens. This modern manufacturing process ensures the enzyme is produced in a highly pure and sustainable form, suitable for human consumption.

Serrapeptase is a commonly used drug (Takeda Chemical Industries) in Japan and Europe. In the U.S., serrapeptase is classified as a dietary supplement. Brand names for serrapeptase include Danzen, Serodase, Nemesulide, and Antiflazym.

Common Dosage Forms

Enteric-coated oral capsules/tablets are the preferred form for systemic/mucolytic claims, as they protect the enzyme from gastric acid. Non-enteric powders/capsules offer lower cost but the enzyme is likely degraded in the stomach. Topical gels and wound dressings remain investigational for localized proteolysis and biofilm disruption.

Enteric-coated oral formulation of this enzyme is being used commonly in various specialties like surgery, orthopaedics, otolaryngology, gynaecology, and dentistry for its anti-inflammatory and anti-edemic properties. This enteric coating consists of pH-sensitive polymers which remain intact in the gastric acidic pH (1.5–3.5) and solubilize in the more favourable alkaline pH (6.5–7.6) of the small intestines.

---

2. Historical and Traditional Use

Unlike botanical herbal medicines with documented ancient use, serrapeptase does not have a documented history spanning centuries of traditional medicine. Its origin is modern: in the 1960s, researchers in Japan isolated this enzyme and began exploring its potential health applications. Today, serrapeptase is produced through fermentation processes using the bacterium Serratia E15.

Serrapeptase (EC number 3.4.24.40) is an effective proteolytic enzyme belonging to the serine protease family that first came into interest to Japanese biochemists approximately 25 years ago, since when it has been used widely in health care in Asian and European countries. Serrapeptase made its debut in the United States in 1977.

The use of proteolytic enzymes like trypsin, chymotrypsin, and bromelain came into practice in the United States during the 1950s after it was observed that they had anti-inflammatory effects. The same observation was made with serrapeptase in Japan during the late 1960s when researchers initially isolated the enzyme from the silkworm. In fact, researchers in Europe and Japan proposed that serrapeptase was the most effective proteolytic enzyme for reducing inflammation.

Japanese researchers were the first to report and introduce the anti-inflammatory drug serratiopeptidase to the world. Enzyme formulations were created and were widely used as medicines. After 1970, these enzyme formulations were eventually successfully marketed worldwide. The clinical studies carried out by researchers in Europe and Japan suggested serratiopeptidase as a potent anti-inflammatory drug.

Some sources indicate use in Asian medical traditions. It was used in traditional Asian medicine, particularly in China and Japan, to help reduce inflammation and aid in wound healing. It was valued for promoting natural healing processes. Over time, serrapeptase gained recognition beyond Asia, especially in Europe, where it became a popular natural anti-inflammatory. However, it should be noted that these assertions regarding traditional Asian use lack detailed documentation in peer-reviewed sources, and the most rigorously documented history of serrapeptase begins with its laboratory isolation and pharmaceutical development in Japan in the late 1960s.

The enzyme was used in Japan under pharmaceutical designation (notably under the trade name Danzen by Takeda Chemical Industries) and in European countries as an approved pharmaceutical, before later transitioning in many markets, especially the United States, to a dietary supplement category.

---

3. Key Constituents and Biochemical Character

Serrapeptase is itself the active principle — it is a single-component enzyme rather than a multi-constituent botanical extract. Its biochemical properties are well established.

• Enzyme class: Serratiopeptidase (EC 3.4.24.40), also known as serrapeptase and serralysin, is a type of metalloendopeptidase possessing anti-edemic, anti-inflammatory, analgesic, fibrinolytic, and anti-atherosclerotic properties, and has been directly employed in clinical therapy in regulation of inflammation and pain.
• Catalytic metal: The enzyme contains zinc at the active site. This zinc ion coordinates with conserved histidine and glutamate residues in the active site to drive the hydrolysis of peptide bonds.
• Molecular weight and structure: The serrapeptase enzyme has a molecular weight of 45,000–60,000 Da and is comprised of 470 amino acids in length; it is classified as a metalloprotease due to containing a zinc molecule which helps catalyze its enzymatic activity.
• Thermal stability: Although it shows maximal activity at 40°C and a pH of 9.0, it is fully inactivated at 55°C for 15 minutes.
• Amino acid composition: The amino acid sequence is free of sulfur-containing amino acids (cysteine and methionine).
• Enzyme activity units: The doses typically used in studies range from 10 mg to 60 mg per day. The enzymatic activity of serrapeptase is measured in units, with 10 mg equalling 20,000 units of enzyme activity.

---

4. Mechanisms of Action

Serrapeptase's therapeutic properties are attributed to several distinct but overlapping biochemical mechanisms.

4.1 Proteolytic Breakdown of Inflammatory Proteins

As a proteolytic enzyme, serrapeptase specifically targets and degrades non-living protein matter, such as fibrin, a protein involved in blood clotting, and other dead or damaged tissues. This ability to selectively digest these proteins underlies its anti-inflammatory and pain-relieving properties.

Inflammation is a complex biological response to harmful stimuli, and it often involves the accumulation of fluid and proteins in the affected area. Serrapeptase aids in reducing this accumulation by breaking down these proteins, which can decrease the swelling and pain associated with inflammation. By digesting the proteins that contribute to the inflammatory response, serrapeptase can effectively reduce the symptoms of conditions like arthritis, sinusitis, and other inflammatory disorders.

4.2 Anti-Edemic Effects

Proteolytic degradation of fibrinous exudates and extracellular matrix components reduces the scaffolding that traps fluid and inflammatory cells, facilitating resorption of edema and decreased tissue swelling. This is considered one of the primary rationales for its use in postoperative and post-traumatic settings.

4.3 Fibrinolytic Activity

Serratiopeptidase is a proteolytic enzyme prescribed in various specialties for its anti-inflammatory, anti-edemic, and analgesic effects. Some anecdotal reports suggest it to possess anti-atherosclerotic effects also, due to its fibrinolytic and caseinolytic properties.

Because the enzyme metabolizes non-living tissues while leaving living tissue intact, it might be useful for eliminating fatty material, cholesterol, cellular waste products, calcification, and fibrin accumulation on the interior of the capillaries. SRP's fibrinolytic (clot removal) action may also aid with thicker blood, in cases of elevated risk of stroke, and phlebitis/thrombophlebitis.

4.4 Mucolytic Activity

Proteolytic cleavage of mucin protein subunits reduces mucus viscosity and adhesiveness, facilitating expectoration and drainage.

Another key mechanism is the enzyme's ability to thin mucus. In conditions like chronic sinusitis or bronchitis, the mucus can become thick and difficult to expel. Serrapeptase helps by breaking down the protein structure of the mucus, thereby making it less viscous and easier to clear from the body.

4.5 Modulation of Inflammatory Mediators

SEPD (serratiopeptidase) has been shown to exert anti-inflammatory effects by reducing inflammatory cytokines and adhesion molecules, thus regulating inflammatory cell movement to the site of inflammation.

Research in animal models of vascular inflammation suggests additional effects on chemokine expression: lipopolysaccharide (LPS) has potent pro-inflammatory properties and acts on many cell types including vascular endothelial cells. The secretion of the cytokines MCP-1 (CCL2), interleukins, and the elevation of oxidative stress by LPS-activated vascular endothelial cells contribute substantially to the pathogenesis of vascular inflammation. Preclinical studies have examined whether serrapeptase can modulate these pathways, though translation to humans remains unconfirmed.

4.6 Anti-Biofilm Activity

Enzymatic proteolysis of proteinaceous components of bacterial biofilms reduces structural integrity, increasing antibiotic penetration and immune access to bacteria.

Serrapeptase (SPT), a proteolytic enzyme, has emerged as a potential anti-biofilm agent due to its ability to degrade biofilm components and disrupt bacterial adhesion. In vitro assays, including crystal violet staining, optical and fluorescence microscopy, and viability measurements, revealed dose-dependent inhibition of biofilm formation (IC₅₀ = 14.2 ng/mL), reduced biofilm (−92% at 500 ng/mL) and planktonic viability (−45% at 500 ng/mL), and a marked loss of amyloid curli fibers.

Studies involving Staphylococcus aureus have also reported anti-biofilm effects: serrapeptase (SPT), a protease of Serratia marcescens, possesses antimicrobial properties similar or superior to those of many antibiotics. Anti-biofilm activity was demonstrated against S. aureus (ATCC 25923, methicillin-susceptible strain, MSSA) and MRSA (ST80), with IC₅₀ values of 0.67 μg/mL and 7.70 μg/mL, respectively. SPT affected bacterial viability, causing a maximum inhibition of −46% and −27%, respectively. These findings are currently from in vitro research.

4.7 Analgesic Mechanism

By reducing edema, fibrinous entrapment, and inflammatory mediator retention in tissues, serrapeptase can decrease mechanical and chemical nociceptive stimulation. The enzyme is not thought to act directly on pain receptors but rather to remove the physical and biochemical stimuli that trigger pain signals.

---

5. Scientific Evidence by Area of Use

Overview of the Evidence Base

A PubMed search using keywords 'Serratiopeptidase' or 'Serrapeptase' revealed 74 results, showing 16 clinical trials, out of which 9 were RCTs related to efficacy of serratiopeptidase. A 2013 systematic review in the International Journal of Surgery remains one of the most comprehensive assessments of the field. Various published studies have reflected the use of serratiopeptidase for its anti-inflammatory, anti-edemic, and analgesic effects. Some anecdotal studies suggest it to possess anti-atherosclerotic effects also. There were 6 clinical studies supporting the anti-inflammatory effects of serratiopeptidase.

Critically, limitations included small sample size, poorly defined enrollment criteria and outcomes, unclear statistical methods, short duration, and failure of some studies to report the dose and duration of therapy. Many studies on serrapeptase were poorly structured, with inadequate control groups. The most recent data suggests that serrapeptase is not a very effective supplement, as far as joint health and inflammation is concerned.

5.1 Dental and Oral Surgery (Post-Operative Swelling, Pain, and Trismus)

This is the most extensively studied clinical area for serrapeptase, with the greatest density of controlled trials.

Serratiopeptidase for pain, facial swelling, and trismus associated with surgical removal of impacted molar is under investigation. However, conclusive evidence on the use of serratiopeptidase is lacking. Hence, a systematic review and meta-analysis of randomized controlled studies was carried out by Sivaramakrishnan and Sridharan, published in the Journal of Maxillofacial and Oral Surgery in 2018.

A meta-analysis based on five human clinical trials by Sivaramakrishnan and Sridharan suggested substantial benefits of serratiopeptidase after surgical removal of impacted molars. Serratiopeptidase statistically reduced trismus after extraction in comparison with corticosteroids and ibuprofen. Swelling was better with corticosteroids on the first day, and no significant results were noticed during follow-up. However, serratiopeptidase analgesic actions are the subject of debate and there is so far no conclusive statement on their efficacy. The limitations imposed on assessing the potential clinical efficacy of serratiopeptidase after third molar surgery must be acknowledged.

The quality of studies for both outcomes was graded as low. Data could not be pooled for pain, as each study utilized a different comparator.

A 2021 randomized controlled clinical trial published in BMC Oral Health reported that: in this clinical trial 133 patients (mean age 23 years, 54% female) completed the study. Baseline characteristics were comparable across treatment groups. Serratiopeptidase significantly improved trismus compared with control on the 4th day.

A 2009 randomized, double-blind, placebo-controlled study (Chopra et al.) compared the efficacy and safety of paracetamol, serratiopeptidase, ibuprofen, and betamethasone using the dental impaction pain model.

Evidence strength: Moderate in breadth (multiple RCTs), but low-to-moderate in quality due to small sample sizes, methodological heterogeneity, and variable outcome measures.

5.2 ENT Inflammation (Ear, Nose, and Throat Conditions)

One study looked at the effects of serrapeptase in nearly 200 people with inflammatory ear, nose, and throat conditions. Researchers found that the participants who supplemented with serrapeptase had significant reductions in pain severity and mucus production compared to those who took a placebo.

This refers to the Mazzone et al. (1990) multicentre, double-blind, randomized trial versus placebo evaluating Serratia-peptidase in acute or chronic inflammation of otorhinolaryngology pathology, published in the Journal of International Medical Research. This study is one of the five randomized controlled trials identified as having a relatively low risk of bias in the 2013 systematic review.

Evidence strength: Limited; one qualifying placebo-controlled RCT exists for this indication, representing low overall evidence.

5.3 Respiratory Disease and Mucolysis

A key human clinical study in this area is the Nakamura et al. (2003) trial, published in Respirology: the proteolytic enzyme serrapeptase (SER) is widely used in clinical practice in Japan. The investigators examined the effect of SER on sputum properties and symptoms in patients with chronic airway diseases. This study was an open-labelled trial with a non-treatment control group. Patients were randomly assigned to oral treatment with (n = 15) and without (n = 14) SER 30 mg/day for 4 weeks. Patients collected sputum samples for about 4 h in the morning on the day the trial began and 4 weeks later.

However, the study's conclusions were notable for their negative finding: this work investigated the effect of SER on sputum properties and symptoms in patients with chronic airway diseases and concluded that the proteolytic enzyme serrapeptase should be eliminated from clinical practice.

Other conditions evaluated in the low-quality studies included postoperative or traumatic swelling, carpal tunnel syndrome, secretory otitis media, and chronic airway disease, but the resulting evidence was insufficient to evaluate the efficacy of serrapeptase for these indications.

Theoretically, SEPD may be a promising therapeutic candidate for repurposing due to its immunomodulatory, anti-inflammatory, mucolytic, antifibrotic, antithrombotic, antiviral, and fibrinolytic properties. However, such claims are hypothesis-based, not confirmed by large-scale RCTs in respiratory disease.

Evidence strength: Weak to absent for clinical respiratory benefit. The primary human trial was open-label, small, and its authors recommended against clinical use.

5.4 Post-Partum Breast Engorgement

A 1989 randomized, placebo-controlled clinical trial (Kee et al.) evaluated serrapeptase 30 mg/day for 3 days in women with postpartum breast engorgement. On a composite score that considered swelling, induration, and impaired breastfeeding, the incidence of marked or moderate improvement was 85.7% with serrapeptase and 60% with placebo (P<0.05).

A 2016 updated Cochrane review of best treatments for breast engorgement during lactation identified only the above study from 1989 that investigated the use of serrapeptase.

Evidence strength: Very low. A single 1989 placebo-controlled trial exists, and a 2016 Cochrane review found no additional studies. The evidence base is too thin to draw conclusions.

5.5 Carpal Tunnel Syndrome

A preliminary trial of serratiopeptidase in patients with carpal tunnel syndrome was published in the Journal of the Association of Physicians of India in 2000 (Malshe PC). Two low-quality studies evaluated serrapeptase as an adjunct to increase the penetration of antimicrobial drugs into sites of infection. Other conditions evaluated in low-quality studies included postoperative or traumatic swelling, carpal tunnel syndrome, secretory otitis media, and chronic airway disease, but the resulting evidence was insufficient to evaluate the efficacy of serrapeptase for these indications.

Evidence strength: Preliminary only. A single small pilot trial exists. No confirmatory RCTs have been published. No conclusions can be drawn.

5.6 Biofilm Disruption and Antibiotic Potentiation

Serrapeptase has the potential to enhance the activity of antibiotics by inhibiting the production of biofilms and adhesion to host tissue.

In an animal model study examining implant-related infection, microbiological testing suggested that infection persisted in only one (5.6%) of eighteen animals in the serratiopeptidase-and-antibiotic group, whereas it was present in six (37.5%) of sixteen animals in the antibiotic-only group (p = 0.001). Histological evaluation showed similar results (kappa = 0.92). Serratiopeptidase was effective for eradicating infection caused by biofilm-forming bacteria in this experimental animal model. The antibiofilm property of the enzyme may enhance antibiotic efficacy in the treatment of staphylococcal infections.

Two low-quality studies evaluated serrapeptase as an adjunct to increase the penetration of antimicrobial drugs into sites of infection. One of the referenced studies is Koyama et al. (1986), which examined augmentation by serrapeptase of tissue permeation by cefotiam (an antibiotic).

Evidence strength: Preclinical (animal and in vitro) only, with two low-quality human studies. Evidence is insufficient to recommend clinical use for this purpose.

5.7 Osteoarthritis and Joint Pain

One randomized, double-blind study (Klein & Kullich, 2000) evaluated short-term treatment of painful osteoarthritis of the knee with oral enzymes, comparing against diclofenac. However, this study used an enzyme combination product, making attribution to serrapeptase alone difficult.

Many studies on serrapeptase were poorly structured, with inadequate control groups. The most recent data suggests that serrapeptase is not a very effective supplement, as far as joint health and inflammation is concerned.

Evidence strength: Weak. Very few trials isolate serrapeptase for musculoskeletal pain, and available evidence does not support a reliable anti-arthritic effect.

5.8 Cardiovascular and Fibrinolytic Applications

Serratiopeptidase (EC 3.4.24.40), also known as serrapeptase and serralysin, which is a type of metalloendopeptidase, possesses anti-edemic, anti-inflammatory, analgesic, fibrinolytic, and anti-atherosclerotic properties and has been directly employed in clinical therapy in regulation of inflammation and pain; furthermore, serrapeptase is even being used as a health supplement to protect the heart from atherosclerosis, which was achieved by degradation of atherosclerotic plaque and fibrin on the inside of arteries.

Published analyses of serrapeptase's fibrinolytic properties conclude it theoretically reduces clot formation rather than increasing thrombosis risk. However, clinical evidence is insufficient and of poor quality, with inadequate studies lacking long-term safety data, advising against its use for cardiovascular or antithrombotic indications.

Evidence strength: Theoretical and preclinical only. No adequately powered human RCTs have established cardiovascular benefit. This application remains speculative.

---

6. Body Systems Associated with Serrapeptase

• Musculoskeletal system: Used for postoperative swelling reduction, joint inflammation, and trismus following oral surgery. Evidence is limited but most robust in the dental surgery context.
• Respiratory system: Proposed as a mucolytic agent to reduce sputum viscosity and improve clearance in chronic airway disease. Human clinical evidence is weak and contradictory.
• Ear, nose, and throat (ENT): Studied for acute and chronic inflammatory ENT conditions; one qualifying placebo-controlled RCT shows benefit for pain and mucus.
• Cardiovascular system: Proposed anti-atherosclerotic and fibrinolytic effects based on the enzyme's ability to degrade fibrin; no robust human trial evidence exists.
• Immune and infectious disease: Anti-biofilm activity studied in vitro and in animal models as an adjunct to antibiotic therapy; no confirmatory human RCTs.
• Reproductive system: A single 1989 trial examined use for postpartum breast engorgement with statistically significant results, but the Cochrane Library has identified no confirmatory studies.

---

7. Dosage Forms and Doses Reported in Studies

The doses typically used in studies range from 10 mg to 60 mg per day. The enzymatic activity of serrapeptase is measured in units, with 10 mg equalling 20,000 units of enzyme activity.

Specific doses reported in identified human clinical studies include:

• Nakamura et al. (2003), chronic airway disease: Patients were randomly assigned to oral treatment with (n = 15) and without (n = 14) SER 30 mg/day for 4 weeks.
• Kee et al. (1989), breast engorgement: Serrapeptase 30 mg/day for 3 days (as cited in the 2013 systematic review and the drugs.com monograph).
• COVID-19 adjuvant hypothesis: A dose of 10 mg thrice daily was proposed for examination as an adjuvant in COVID-19. This was a hypothesis paper; no clinical trial has confirmed this dose.

Human pharmacokinetics of intact serrapeptase are poorly quantified; validated plasma bioavailability percentages are not established in standardized studies. Where absorption occurs: if enteric coating survives gastric transit, release occurs in the proximal small intestine (duodenum/jejunum).

Serrapeptase is a protein enzyme that is destroyed by stomach acid. Enteric coating protects it until it reaches the alkaline environment of the small intestine, where it is absorbed intact into the bloodstream. Without enteric coating, most of the enzyme is inactivated before absorption.

Regarding timing: it should be taken on an empty stomach or at least 30 minutes before eating or two hours after finishing a meal.

---

8. Safety, Adverse Effects, and Interactions

8.1 General Tolerability

Serrapeptase was well tolerated in short-term clinical trials, but long-term safety has not been evaluated.

Using SEPD can be virtuously justified as being safe and effective and devoid of side effects that commonly develop with the use of conventional mucolytics that may cause sedation, euphoria, gastrointestinal disturbances, respiratory irritation, and constipation — probably due to the absence of any interaction with receptors. This characterization applies only to short-term use in published trial settings.

8.2 Reported Adverse Drug Reactions

There are not many published reports of adverse drug reactions (ADRs) to serratiopeptidase. The only information available is drug company monographs. The ADRs include allergic skin reactions which could range from dermatitis to extreme cases of Stevens–Johnson syndrome or erythema multiforme, muscle aches and joint pains, gastric disturbances like anorexia, nausea and abdominal upset, and rarely cough or pneumonia.

Rare, serious adverse effects reported with serrapeptase include eosinophilic pneumonitis, bullous pemphigoid, hemorrhage in a patient with Behçet disease, and possibly Stevens-Johnson syndrome.

The case of serrapeptase-induced eosinophilic pneumonitis was reported in the literature as Sasaki S, Kawanami R, Motizuki Y et al. (2000), published in Nihon Kokyuki Gakkai Zasshi. This represents a rare but serious pulmonary adverse event that has been cited repeatedly in systematic reviews of the drug's safety profile.

8.3 Drug and Supplement Interactions

Serrapeptase should not be taken along with blood thinners — such as warfarin and aspirin — or other dietary supplements like garlic, fish oil, and turmeric, which may increase the risk of bleeding or bruising.

There are no clinical studies formally reporting specific drug interactions with serratiopeptidase. The bleeding risk concern is extrapolated from the enzyme's known fibrinolytic and anti-platelet aggregation mechanisms rather than confirmed through pharmacokinetic interaction studies.

8.4 Special Populations and Contraindications

Serrapeptase is not suitable for all people, particularly for people with bleeding disorders and those taking blood thinners.

This product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

8.5 Perioperative Use

Because of its fibrinolytic and antiplatelet properties, use of serrapeptase before surgery or invasive medical procedures warrants specific attention. Its ability to degrade fibrin — the protein critical to normal haemostasis — means it could theoretically prolong bleeding times, though formal pharmacological studies quantifying this risk in surgical humans are lacking.

8.6 Regulatory Status

The FDA has not reviewed serrapeptase for safety and effectiveness. The FDA has not tested serrapeptase products to confirm that they contain the ingredients stated on their labels. In Japan and parts of Europe, serrapeptase has been or continues to be used under pharmaceutical designation, subject to regulatory oversight in those jurisdictions.

---

Summary of Evidence Strengths and Weaknesses

Across all indications studied, the evidence for serrapeptase exhibits recurring limitations. Despite being widely used, there are few published studies regarding its efficacy. Thus, evidence regarding its clinical utility is needed. The most robust evidence — from multiple small RCTs and one meta-analysis — comes from the oral surgery/dental domain, specifically for reduction of trismus following impacted molar removal. Evidence in ENT, respiratory, cardiovascular, and other domains is either from single low-quality trials or purely preclinical. Anti-biofilm effects are promising in laboratory and animal models but have not been validated in large human clinical trials.

The 2013 systematic review (Bhagat, Agarwal, and Roy, International Journal of Surgery) remains the most comprehensive synthesis of the clinical evidence and concluded that while several individual studies reflected use for anti-inflammatory, anti-edemic, and analgesic effects, the overall quality and volume of evidence was insufficient to support broad therapeutic claims.

---

References

• Wikipedia: Serratiopeptidase
• Sharma C et al. (2021). Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug, Can Be a Useful Adjuvant for Management in COVID-19. Frontiers in Pharmacology. PMC8265778
• Bhagat S, Agarwal M, Roy V. (2013). Serratiopeptidase: A systematic review of the existing evidence. International Journal of Surgery. ScienceDirect
• Sivaramakrishnan G, Sridharan K. (2018). Role of Serratiopeptidase After Surgical Removal of Impacted Molar: A Systematic Review and Meta-analysis. Journal of Maxillofacial and Oral Surgery. PMC5878179
• Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial. PMC7927242
• Serratiopeptidase Attenuates Lipopolysaccharide-Induced Vascular Inflammation by Inhibiting the Expression of Monocyte Chemoattractant Protein-1. PMC10047379
• Purification, characterization, and structural elucidation of serralysin-like alkaline metalloprotease from a novel source. PMC6821148
• Nakamura S et al. (2003). Effect of the proteolytic enzyme serrapeptase in patients with chronic airway disease. Respirology. DOI: 10.1046/j.1440-1843.2003.00482.x
• Serratiopeptidase: Insights into the therapeutic applications. ScienceDirect
• Serratiopeptidase. Encyclopedia MDPI
• Ethiraj S, Gopinath S. (2017). Production, purification, characterization, immobilization, and application of Serrapeptase: a review. Frontiers in Biology. DOI: 10.1007/s11515-017-1461-3
• Examine.com: Serrapeptase — benefits, dosage, and side effects
• Examine.com: Research Breakdown on Serrapeptase
• Drugs.com: Serrapeptase Uses, Benefits & Dosage (Natural Product monograph)
• Cell-Free Expression of a Therapeutic Protein Serratiopeptidase. PubMed PMID 37049893
• Serrapeptase impairs biofilm, wall, and phospho-homeostasis of resistant and susceptible Staphylococcus aureus. PMC9898353
• Serrapeptase Eliminates Escherichia coli Biofilms by Targeting Curli Fibers, Lipopolysaccharides, and Phosphate Metabolism. PMC12388453
• Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis — A Pilot Study. PMC8624573
• Efficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trial. BMC Oral Health. Springer